Beneficial effects of a Multistrain Bifidobacterium probiotic on gut health and immunity of indonesian children
Abstract
Modulating the gut microbiota using probiotics has been shown to help maintain gut microbiota and support immune function. This study aimed to evaluate the effects of growing-up milk supplemented with a multistrain Bifidobacterium probiotic on gut microbiota, short-chain fatty acids (SCFAs), immune markers, and diarrhea episodes in healthy children. In a double-blind, randomized, placebo-controlled trial, 102 healthy children aged 1 to 3 years old received an intervention product containing a multistrain probiotic comprising Bifidobacterium longum BB536, Bifidobacterium breve M-16V, and Bifidobacterium longum subsp. infantis M-63 (6.9 × 10⁷ CFU/serving/strain), and galacto-oligosaccharides (GOS) or a placebo with GOS but without probiotic strains for 90 days following a 14-day baseline period. Fecal samples were collected on days 15 and 105 for microbiota, SCFA, and immune marker analyses, while diarrhea parameters were assessed using the Bristol Stool Chart and defecation frequency. The probiotic group showed a significant 1.2-log increase (p=0.00069) in total viable Bifidobacterium, although this was not significantly different from the placebo group. Quantitative PCR confirmed significant increases in Bifidobacterium strains between groups (p<0.05), except for B. infantis. Enterobacteriaceae increased significantly in the placebo group (p=0.01) but remained stable in the probiotic group. In the probiotic group, SCFA concentrations and IL-10 (p=0.0098) increased significantly, while IL-8 remained stable, although no differences were observed between groups. A lower prevalence of diarrhea was observed in the probiotic group, although the difference was not statistically significant. Overall, the multistrain Bifidobacterium probiotic demonstrated the ability to colonize the gastrointestinal tract and may support gut microbiota, the gut environment, and immune function.
Related
- Effects of a multistrain probiotic formulation on immune response and microbiome modulation following influenza vaccination in adults: a randomised, triple-blind, placebo-controlled trial
- NOD2 restrains probiotic-mediated TLR2-dependent antitumor immunity
- Potential mechanisms of Bifidobacterium-mediated synergistic antibiotic eradication of drug-resistant Helicobacter pylori
- Inferring the age of a fixed beneficial allele.
- Azithromycin Derivatives to Mitigate Off-Target Inhibition of Autophagy and Retain Beneficial Host Directed Effects
BibTeX
@article{suroto2026beneficial,
title = {{Beneficial effects of a Multistrain Bifidobacterium probiotic on gut health and immunity of indonesian children}},
author = {Dian Anggraini SUROTO and Mariyatun MARIYATUN and Mifta GATYA and Adina Amy REIKANISUJI and Putrika Citta PRAMESI and Darmawan Ari NUGROHO and Dian Kesumapramudya NURPUTRA and Tyas UTAMI and Ruth Audy ALEXANDER and Iwan Surjadi HANDOKO and Endang Sutriswati RAHAYU},
journal = {Bioscience of Microbiota, Food and Health},
year = {2026},
month = oct,
doi = {10.12938/bmfh.2026-051},
url = {https://www.jstage.jst.go.jp/article/bmfh/advpub/0/advpub_2026-051/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Beneficial effects of a Multistrain Bifidobacterium probiotic on gut health and immunity of indonesian children
AU - Dian Anggraini SUROTO
AU - Mariyatun MARIYATUN
AU - Mifta GATYA
AU - Adina Amy REIKANISUJI
AU - Putrika Citta PRAMESI
AU - Darmawan Ari NUGROHO
AU - Dian Kesumapramudya NURPUTRA
AU - Tyas UTAMI
AU - Ruth Audy ALEXANDER
AU - Iwan Surjadi HANDOKO
AU - Endang Sutriswati RAHAYU
PY - 2026
DA - 2026/10/01
JO - Bioscience of Microbiota, Food and Health
DO - 10.12938/bmfh.2026-051
UR - https://www.jstage.jst.go.jp/article/bmfh/advpub/0/advpub_2026-051/_article
AB - Modulating the gut microbiota using probiotics has been shown to help maintain gut microbiota and support immune function. This study aimed to evaluate the effects of growing-up milk supplemented with a multistrain Bifidobacterium probiotic on gut microbiota, short-chain fatty acids (SCFAs), immune markers, and diarrhea episodes in healthy children. In a double-blind, randomized, placebo-controlled trial, 102 healthy children aged 1 to 3 years old received an intervention product containing a multistrain probiotic comprising Bifidobacterium longum BB536, Bifidobacterium breve M-16V, and Bifidobacterium longum subsp. infantis M-63 (6.9 × 10⁷ CFU/serving/strain), and galacto-oligosaccharides (GOS) or a placebo with GOS but without probiotic strains for 90 days following a 14-day baseline period. Fecal samples were collected on days 15 and 105 for microbiota, SCFA, and immune marker analyses, while diarrhea parameters were assessed using the Bristol Stool Chart and defecation frequency. The probiotic group showed a significant 1.2-log increase (p=0.00069) in total viable Bifidobacterium, although this was not significantly different from the placebo group. Quantitative PCR confirmed significant increases in Bifidobacterium strains between groups (p<0.05), except for B. infantis. Enterobacteriaceae increased significantly in the placebo group (p=0.01) but remained stable in the probiotic group. In the probiotic group, SCFA concentrations and IL-10 (p=0.0098) increased significantly, while IL-8 remained stable, although no differences were observed between groups. A lower prevalence of diarrhea was observed in the probiotic group, although the difference was not statistically significant. Overall, the multistrain Bifidobacterium probiotic demonstrated the ability to colonize the gastrointestinal tract and may support gut microbiota, the gut environment, and immune function.
SN - 2186-3342
ER -